- Home
- FCUV vs NXTC Comparison
FCUV vs NXTC Comparison
Compare FCUV & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCUV
- NXTC
- Stock Information
- Founded
- FCUV 2012
- NXTC 2015
- Country
- FCUV United States
- NXTC United States
- Employees
- FCUV N/A
- NXTC N/A
- Industry
- FCUV Industrial Machinery/Components
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FCUV Industrials
- NXTC Health Care
- Exchange
- FCUV Nasdaq
- NXTC Nasdaq
- Market Cap
- FCUV 15.9M
- NXTC 13.0M
- IPO Year
- FCUV N/A
- NXTC 2019
- Fundamental
- Price
- FCUV $3.25
- NXTC $5.55
- Analyst Decision
- FCUV
- NXTC Strong Buy
- Analyst Count
- FCUV 0
- NXTC 2
- Target Price
- FCUV N/A
- NXTC $25.50
- AVG Volume (30 Days)
- FCUV 67.7K
- NXTC 13.3K
- Earning Date
- FCUV 11-06-2025
- NXTC 11-06-2025
- Dividend Yield
- FCUV N/A
- NXTC N/A
- EPS Growth
- FCUV N/A
- NXTC N/A
- EPS
- FCUV N/A
- NXTC N/A
- Revenue
- FCUV $432,983.00
- NXTC N/A
- Revenue This Year
- FCUV N/A
- NXTC N/A
- Revenue Next Year
- FCUV N/A
- NXTC N/A
- P/E Ratio
- FCUV N/A
- NXTC N/A
- Revenue Growth
- FCUV 140.82
- NXTC N/A
- 52 Week Low
- FCUV $1.80
- NXTC $2.69
- 52 Week High
- FCUV $10.90
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- FCUV 72.74
- NXTC 59.97
- Support Level
- FCUV $2.51
- NXTC $5.19
- Resistance Level
- FCUV $3.18
- NXTC $5.90
- Average True Range (ATR)
- FCUV 0.29
- NXTC 0.28
- MACD
- FCUV 0.14
- NXTC 0.07
- Stochastic Oscillator
- FCUV 85.28
- NXTC 69.03
About FCUV Focus Universal Inc.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.